Aptevo Therapeutics Inc.
APVONasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $3.1M | $12.3M | $4.3M |
| Operating income | −$26.3M | −$24.6M | −$28.9M | −$28.6M | −$21.4M | −$27.5M |
| Net income | −$26.0M | −$24.1M | −$17.4M | $8.0M | −$28.5M | −$17.8M |
| Total assets | $27.2M | $15.6M | $24.8M | $34.2M | $56.6M | $53.5M |
| Total liabilities | $9.8M | $10.8M | $12.6M | $16.2M | $55.4M | $37.0M |
| Equity | $17.4M | $4.8M | $12.2M | $18.0M | $1.2M | $16.6M |
| EPS (diluted) | $-87.27 | $-31460.23 | $-2316.83 | $1.57 | $-6.07 | — |
| Shares out. | 1.5M | 23.5M | 7.2M | 5.0M | 4.4M | 45.3M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −149.4%
- Return on assets
- −95.5%
- Return on capital (ROCE)
- −124.4%
- Liabilities / assets
- 36.1%
- Debt / equity
- 0.56×
- Book value / share
- $11.92
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -33.51distress
- Accruals / assets
- −1.4%clean
- Piotroski F-Score
- 5/7mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 1 warning● 2 good- Altman Z″ in the distress zone
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 87,845 | 1.5 | -4.7% |
| Apr 30, 2026 | 92,205 | 5.1 | -11.6% |
| Apr 15, 2026 | 104,241 | 3.8 | -21.7% |
| Mar 31, 2026 | 133,103 | 2.5 | +18.8% |
| Mar 13, 2026 | 112,000 | 1.0 | -4.1% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Entered a material agreement · Unregistered equity sale · Regulation FD disclosureMay 27, 2026
- Results of operationsMay 13, 2026
- Other material eventMay 6, 2026
- Results of operationsMar 26, 2026
- Other material eventMar 11, 2026
- Shareholder voteFeb 19, 2026
- Director / officer changeFeb 3, 2026
- Entered a material agreement · Unregistered equity sale · Other material eventJan 9, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Corporate family
Spun off from Emergent BioSolutions IncEBS · Aug 1, 2016
From the spin-off filings we track. Follow a company to walk its own history.
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.